- Robust portfolio and solid organic growth counterbalance difficult market environment and negative foreign exchange effects
- All business units contribute to organic growth, especially in Emerging Markets
- Profitability increases by approximately one percentage point owing to strong business performance and strict cost control
| XLS |
|
Merck Millipore | Key figures |
|||
|
|
|
|
|
|
|
|
|
|
|
€ million |
2013 |
2012 |
Change in % |
|
Total revenues |
2,645.3 |
2,616.9 |
1.1 |
|
Sales |
2,627.5 |
2,598.2 |
1.1 |
|
Operating result (EBIT) |
262.0 |
251.7 |
4.1 |
|
Margin (% of sales) |
10.0 |
9.7 |
|
|
EBITDA |
589.8 |
560.9 |
5.2 |
|
Margin (% of sales) |
22.4 |
21.6 |
|
|
EBITDA pre one-time items |
642.8 |
614.4 |
4.6 |
|
Margin (% of sales) |
24.5 |
23.6 |
|
|
Business free cash flow |
493.8 |
511.3 |
–3.4 |
Development of total revenues and sales as well as results of operations
In 2013, the Merck Millipore division generated strong organic sales growth of 5.5% despite a challenging market environment. Biochrom AG, Berlin, which was acquired in 2012, contributed 0.5% to the increase in sales in 2013. Taking into account a negative foreign exchange impact of –4.8%, divisional sales increased by 1.1% to € 2,628 million (2012: € 2,598 million). Currency headwinds stemmed mainly from the Japanese yen, the U.S. dollar, and the Indian rupee. At € 18 million, the royalty, license and commission income recorded by the Bioscience and Process Solutions business units remained at the previous year’s level.
The development of sales in the individual quarters in comparison with 2012 as well as the respective organic growth rates are presented in the following table:
Merck Millipore | Sales and organic growth by quarter 1
search hit 44
